Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fluorine-18 PSMA 1007 - Advanced Biochemical Compounds (ABX GmbH)

Next Previous
Drug Profile

Fluorine-18 PSMA 1007 - Advanced Biochemical Compounds (ABX GmbH)

Alternative Names: [18F]-PSMA-1007; F-18-PSMA-1007; Fluorine-18 PSMA 1007 - ABX advanced biochemical compounds GmbH; PB-01 - Primo Biotechnology; Radelumin

Latest Information Update: 20 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator German Cancer Research Center
  • Developer Advanced Biochemical Compounds (ABX GmbH); Centre for Probe Development and Commercialization
  • Class Amides; Imaging agents; Naphthalenes; Pyridines; Radioisotopes; Radiopharmaceutical diagnostics; Urea compounds
  • Mechanism of Action Positron-emission tomography enhancers; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Prostate cancer
  • Phase II Glioblastoma

Most Recent Events

  • 30 Jun 2026 Primo Biotechnology completes a phase-I clinical trials in Prostate cancer (Diagnosis) in Taiwan (Parenteral) (NCT06935149)
  • 31 Oct 2025 Phase-I clinical trials in Prostate cancer (Diagnosis) in Taiwan (Parenteral) (NCT06935149)
  • 05 May 2025 ABX advanced biochemical compounds completes a phase III trial in Prostate cancer (Diagnosis) in Netherlands, USA, Switzerland (IV) (NCT04742361) (EUdraCT2020-004235-24)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top